DC_AC50
CAS No. 497061-48-0
DC_AC50( —— )
Catalog No. M24456 CAS No. 497061-48-0
DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 38 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 95 | In Stock |
|
| 25MG | 178 | In Stock |
|
| 50MG | 281 | In Stock |
|
| 100MG | 421 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDC_AC50
-
NoteResearch use only, not for human use.
-
Brief DescriptionDC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones).
-
DescriptionDC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.DC_AC50 binding to Atox1 and CCS and reducing cancer cell proliferation and tumour growth.
-
In VitroCell Viability Assay Cell Line:Canine OSA (Abrams, D1 and human OSA (HOS, MG63) cells.Concentration:0-10 μM.Incubation Time:72 h.Result:Dose-dependently decreased viability of OSA cells.Apoptosis AnalysisCell Line:Abrams and HOS cells.Concentration:1, 3 and 10 μM (10 μM Carboplatin).Incubation Time:24 h.Result:Potentiated carboplatin-induced apoptosis.
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorAtox1|CCS|Apoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number497061-48-0
-
Formula Weight424.26
-
Molecular FormulaC17H12BrF2N3OS
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESNC1=C(SC2=C1C=C3CCCC3=N2)C(NC4=C(Br)C=C(C=C4F)F)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jordon M Inkol, et al. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. Vet Comp Oncol. 2020 Dec;18(4):559-569.
molnova catalog
related products
-
Glyphosate
Glyphosate is an herbicide. It also is a possible carcinogen to humans.
-
Lirentelimab
Lirentelimab (AK002) is a humanized anti-sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) antibody that induces apoptosis of IL-5-activated eosinophils and inhibits IL-5-mediated mast cell activation, and is used in the study of refractory inert systemic mastocytosis and allergic conjunctivitis.
-
Tafasitamab
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
Cart
sales@molnova.com